ImmunoTerapia: ImmunoTherapy: The New Frontiers in Medicine
IDO pathway inhibitor Indoximod in combination with Pembrolizumab, an anti-PD1 checkpoint inhibitor, for patients with advanced melanoma
The indoleamine 2,3-dioxygenase ( IDO ) pathway is a key counter-regulatory mechanism that normally inhibits immune responses when appropriate. In the setting of cancer, IDO pathway-mediated immune …
Advanced lung cancer: five-year survival rate for Nivolumab-treated patients much higher than historical rate
Treatment with the immune checkpoint inhibitor Nivolumab ( Opdivo ) has yielded durable responses in some patients with advanced non-small cell lung cancer ( NSCLC ), with a five-year survival rate of …
Axalimogene filolisbac is an active therapy in metastatic cervical cancer
Data from the GOG-0265 study were presented at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer. GOG-0265 is a single arm, phase 2 trial evaluating Axalimogene filolisbac for …
Cancer treatment with anti-PD-1 / PD-L1 agents: PD-L1 expression is not a biomarker for patient selection
Strategies to help improve the efficacy of the immune system against cancer represent an important innovation, with recent attention having focused on anti-programmed death (PD)-1 / PD-ligand 1 (L1) m …
Metastatic urothelial carcinoma: safety, clinical activity, and PD-L1 expression of Avelumab, an anti-PD-L1 antibody
Avelumab is a fully human anti-PD-L1 IgG1 antibody being investigated in multiple clinical trials. Safety and clinical activity of Avelumab as a second-line therapy in patients with metastatic uro …